Literature DB >> 32660991

Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Gina Wall1, Jose L Lopez-Ribot2.   

Abstract

Fungal organisms are ubiquitous in nature, and progress of modern medicine is creating an expanding number of severely compromised patients susceptible to a variety of opportunistic fungal infections. These infections are difficult to diagnose and treat, leading to high mortality rates. The limited antifungal arsenal, the toxicity of current antifungal drugs, the development of resistance, and the emergence of new multidrug-resistant fungi, all highlight the urgent need for new antifungal agents. Unfortunately, the development of a novel antifungal is a rather long and expensive proposition, and no new classes of antifungal agents have reached the market in the last 2 decades. Drug repurposing, or finding new indications for old drugs, represents a promising alternative pathway to drug development that is particularly appealing within the academic environment. In the last few years, there has been a growing interest in repurposing approaches in the antifungal arena, with multiple groups of investigators having performed screenings of different repurposing libraries against different pathogenic fungi in search for drugs with previously unrecognized antifungal effects. Overall, these repurposing efforts may lead to the fast deployment of drugs with novel antifungal activity, which can rapidly bring benefits to patients, while at the same time reducing health care costs.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antifungal agents; antifungal drug development; drug repurposing; fungal infections; repositioning

Mesh:

Substances:

Year:  2020        PMID: 32660991      PMCID: PMC7449171          DOI: 10.1128/AAC.00924-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  72 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.

Authors:  Robert J Bastidas; Cecelia A Shertz; Soo Chan Lee; Joseph Heitman; Maria E Cardenas
Journal:  Eukaryot Cell       Date:  2011-12-30

3.  Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Authors:  Nathan P Wiederhold; Thomas F Patterson; Anand Srinivasan; Ashok K Chaturvedi; Annette W Fothergill; Floyd L Wormley; Anand K Ramasubramanian; José L Lopez-Ribot
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

4.  Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?

Authors:  Aspasia Katragkou; Emmanuel Roilides; Thomas J Walsh
Journal:  Expert Opin Pharmacother       Date:  2016-06       Impact factor: 3.889

5.  Identification of repositionable drugs with novel antimycotic activity by screening the Prestwick Chemical Library against emerging invasive moulds.

Authors:  Hanane Yousfi; Stéphane Ranque; Carole Cassagne; Jean-Marc Rolain; Fadi Bittar
Journal:  J Glob Antimicrob Resist       Date:  2020-01-28       Impact factor: 4.035

6.  The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Authors:  Kristy Koselny; Julianne Green; Louis DiDone; Justin P Halterman; Annette W Fothergill; Nathan P Wiederhold; Thomas F Patterson; Melanie T Cushion; Chad Rappelye; Melanie Wellington; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 7.  Candida albicans biofilm growth and dispersal: contributions to pathogenesis.

Authors:  Gina Wall; Daniel Montelongo-Jauregui; Bruna Vidal Bonifacio; Jose L Lopez-Ribot; Priya Uppuluri
Journal:  Curr Opin Microbiol       Date:  2019-05-11       Impact factor: 7.934

Review 8.  Our current understanding of fungal biofilms.

Authors:  Gordon Ramage; Eilidh Mowat; Brian Jones; Craig Williams; Jose Lopez-Ribot
Journal:  Crit Rev Microbiol       Date:  2009       Impact factor: 7.624

9.  In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis.

Authors:  Taissa Vieira Machado Vila; Ashok K Chaturvedi; Sonia Rozental; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

10.  Screening of Pharmacologically Active Small Molecule Compounds Identifies Antifungal Agents Against Candida Biofilms.

Authors:  Takao Watamoto; Hiroshi Egusa; Takashi Sawase; Hirofumi Yatani
Journal:  Front Microbiol       Date:  2015-12-22       Impact factor: 5.640

View more
  6 in total

1.  The Antidepressant Sertraline Induces the Formation of Supersized Lipid Droplets in the Human Pathogen Cryptococcus neoformans.

Authors:  Matthew R Breuer; Ananya Dasgupta; Joseph G Vasselli; Xiaorong Lin; Brian D Shaw; Matthew S Sachs
Journal:  J Fungi (Basel)       Date:  2022-06-17

Review 2.  Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antibiotics (Basel)       Date:  2020-07-25

3.  Screening the CALIBR ReFRAME Library in Search for Inhibitors of Candida auris Biofilm Formation.

Authors:  Gina Wall; Emily Chen; Mitchell V Hull; Jose L Lopez-Ribot
Journal:  Front Cell Infect Microbiol       Date:  2020-11-25       Impact factor: 5.293

4.  In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.

Authors:  Dina Ezzat Mahmoud; Ahmed Hassan Ibrahim Faraag; Wael Mohamed Abu El-Wafa
Journal:  World J Microbiol Biotechnol       Date:  2021-10-11       Impact factor: 3.312

5.  Screening the Tocriscreen™ bioactive compound library in search for inhibitors of Candida biofilm formation.

Authors:  Hafsa Abduljalil; Ahmed Bakri; Khawlah Albashaireh; Om Alkhir Alshanta; Jason L Brown; Leighann Sherry; Ryan Kean; Christopher Nile; William McLean; Gordon Ramage
Journal:  APMIS       Date:  2022-07-20       Impact factor: 3.428

6.  Pyrogallol and Fluconazole Interact Synergistically In Vitro against Candida glabrata through an Efflux-Associated Mechanism.

Authors:  Dongting Yao; Guanyi Zhang; Weiqin Chen; Jia Chen; Zhen Li; Xin Zheng; Hongmei Yin; Xiaobo Hu
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.